Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12345678910111213...123124»
  • ||||||||||  erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Study on the Synergistic Mechanism of Photodynamic Therapy Combined With Ferroptosis Inducer to Induce Ferroptosis in Cholangiocarcinoma. (Pubmed Central) -  Dec 10, 2024   
    These findings highlight the connection between metabolic reprogramming and epigenetic regulation and suggest that targeting metabolic pathways may offer new strategies to overcome lenvatinib resistance in HCC. Our findings suggest that Erastin or Lenvatinib can enhance the induction of ferroptosis in cholangiocarcinoma cells by photodynamic therapy by increasing intracellular ROS and inhibiting intracellular antioxidant pathways.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (clinicaltrials.gov) -  Dec 9, 2024   
    P2,  N=51, Active, not recruiting, 
    Our findings suggest that Erastin or Lenvatinib can enhance the induction of ferroptosis in cholangiocarcinoma cells by photodynamic therapy by increasing intracellular ROS and inhibiting intracellular antioxidant pathways. Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Nov 2026 | Trial primary completion date: Jan 2027 --> May 2025
  • ||||||||||  fostroxacitabine bralpamide (MIV-818) / Medivir
    Trial completion date, Trial primary completion date:  MIV-818-101: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations (clinicaltrials.gov) -  Dec 6, 2024   
    P1/2,  N=53, Active, not recruiting, 
    The treatment with lenvatinib plus pembrolizumab or everolimus is less cost-effective than the sunitinib treatment for patients with advanced RCC in China and the United States. Trial completion date: Feb 2024 --> Jun 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  PRIMER-1: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) -  Dec 6, 2024   
    P2,  N=60, Recruiting, 
    Trial completion date: Feb 2024 --> Jun 2025 | Trial primary completion date: Feb 2024 --> Dec 2024 Trial completion date: Jul 2026 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Enrollment change, Trial primary completion date, Checkpoint inhibition, Metastases:  Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Na (clinicaltrials.gov) -  Dec 5, 2024   
    P2,  N=6, Active, not recruiting, 
    Trial completion date: Jul 2026 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028 Recruiting --> Active, not recruiting | N=30 --> 6 | Trial primary completion date: Jun 2025 --> Dec 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Journal:  Oncofetal MCB1 Is a Functional Biomarker for HCC Personalized Therapy. (Pubmed Central) -  Dec 4, 2024   
    Furthermore, treatment of targeted drugs-resistant HCC with adeno-associated virus (AAV) targeting MCB1 or a proteasome inhibitor restores targeted drug response, suggesting their clinical significance in HCC combinational therapy. In conclusion, these findings demonstrate that MCB1 could act as a driver for HCC initiation, a contributor to drug resistance, and a biomarker for individualized HCC therapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor. (Pubmed Central) -  Dec 4, 2024   
    As is proven, PT-EVs exhibit robust tumor cell targeting and efficient receptor-mediated cellular uptake, and the efficacy of chemotherapeutic drugs is improved significantly. These results suggest that this platform could be a valuable tool for efficient isolation of PT-EVs and personalized drug customization, particularly when working with limited clinical samples, thus supporting personalized and precision medicine.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Trial withdrawal:  Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma (clinicaltrials.gov) -  Dec 4, 2024   
    P1/2,  N=0, Withdrawn, 
    This study suggests that the efficacy of pembrolizumab-lenvatinib and atezolizumab-bevacizumab is comparable in first-line treatment of unresectable HCC, the atezolizumab-bevacizumab combination may confer additional benefits for patients with high CPA scores compared to pembrolizumab-lenvatinib. N=47 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Machine learning:  Machine learning based ultrasomics noninvasive predicting EGFR expression status in hepatocellular carcinoma patients. (Pubmed Central) -  Dec 3, 2024   
    The predictive performance of the combined model established by integrating ultrasomics features and clinical baseline characteristics was improved, with the AUC, sensitivity, specificity, and accuracy of the RF machine learning combined model for the training and test dataset reaching 0.937 (95%CI, 0.884-0.971), 0.822 (95%CI, 0.702-0.909); 0.857, 0.833; 0.857, 0.800; 0.857, 0.817, respectively. To predict the status of EGFR expression in HCC patients, the ultrasomics model and combined model created by five machine learning algorithms can be utilized as efficient and noninvasive techniques, and the ultrasomics model and combined model established by RF classifier have the best predictive performance.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) -  Nov 30, 2024   
    Patients should feel confident that they can receive Kampo medicines as supportive care for lenvatinib therapy without a risk of drug interactions that could affect treatment efficacy. Reserpine, a small-molecule regulator of m6A, reverses Lenvatinib-resistant phenotypes, including proliferation, migration and anti-apoptosis, in vitro and in vivo by targeting SMAD3 and down-regulating the m6A level in HCC.
  • ||||||||||  Review, Journal:  Systemic Therapy for Hepatocellular Carcinoma. (Pubmed Central) -  Nov 29, 2024   
    Areas of development include testing immune checkpoint-based regimens in the adjuvant setting after surgery, ablation, or transarterial embolization. Also of interest are studies for patients with Child-Pugh B liver function and adding new checkpoint molecules to the current standard platforms.
  • ||||||||||  Enweida (envafolimab) / 3DMed, Ascletis
    Trial completion date, Trial primary completion date, Metastases:  Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer (clinicaltrials.gov) -  Nov 28, 2024   
    P2,  N=108, Recruiting, 
    Also of interest are studies for patients with Child-Pugh B liver function and adding new checkpoint molecules to the current standard platforms. Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review. (Pubmed Central) -  Nov 28, 2024   
    The potential for lenvatinib to induce significant renal microvascular disease, as demonstrated in this case, emphasizes the importance of vigilant renal monitoring and personalized therapeutic strategies in patients treated with lenvatinib for HCC. Early intervention and dose adjustment may be crucial in preventing severe renal impairment, highlighting the significance of tailored treatment plans in the management of advanced HCC patients especially with pre-existing risk factors.
  • ||||||||||  Folotyn (pralatrexate) / Aurobindo
    Journal:  Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway. (Pubmed Central) -  Nov 25, 2024   
    In HCC cells, knockdown of DHFR or treatment with pralatrexate enhanced the sensitivity of HCC cells to molecularly targeted agents, such as sorafenib, regorafenib, lenvatinib, cabozantinib, or anlotinib...Therefore, pralatrexate upregulates the sensitivity of HCC cells to molecularly targeted drugs. These results expand our understanding of folate metabolism and HCC and can help provide more options for HCC treatment.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis
    Journal:  Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma. (Pubmed Central) -  Nov 20, 2024   
    Cabozantinib is an effective and reasonably well-tolerated treatment option for patients with PDTC. Prospective studies are needed to further investigate the role of cabozantinib in the treatment of PDTC, alone and in combination with other agents including checkpoint inhibitors.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib. (Pubmed Central) -  Nov 19, 2024   
    Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Lenvatinib which it can be used in the treatment of hepatocarcinoma.